Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study

Area of Science:

• Pediatric Pulmonology
• Immunology
• Pharmacology

Background:

• Uncontrolled asthma in children can hinder lung development, potentially causing long-term health issues.
• Type 2 inflammation, driven by IL-4 and IL-13, is a key factor in moderate-to-severe asthma.
• Dupilumab is a monoclonal antibody targeting the IL-4 receptor alpha subunit, thereby inhibiting IL-4 and IL-13 signaling.

Purpose of the Study:

• To evaluate the efficacy of dupilumab in improving lung function in children aged 6-11 with moderate-to-severe asthma.
• To assess the long-term effects of dupilumab on lung growth and development in pediatric asthma patients.
• To analyze spirometry parameters and identify subgroups benefiting most from dupilumab treatment.

Main Methods:

• A 52-week, randomized, double-blind, placebo-controlled phase 3 trial (LIBERTY ASTHMA VOYAGE) was conducted.
• Children with moderate-to-severe asthma received add-on dupilumab or placebo every two weeks.
• Lung function was assessed using spirometry, including forced expiratory volume in 1 second (FEV1) and fractional exhaled nitric oxide (FeNO), in patients with type 2 asthma.

Main Results:

• Dupilumab treatment led to significant improvements in pre- and post-bronchodilator percent-predicted forced expiratory volume in 1 second (ppFEV1) starting at week 2 and sustained for 52 weeks.
• The least-squares mean difference in ppFEV1 versus placebo at week 52 was 7.79 percentage points (P < .001) for pre-bronchodilator and 4.37 points (P = .01) for post-bronchodilator.
• Sustained improvements were observed in other lung function parameters, including forced vital capacity (FVC) and FEV1/FVC ratio, across all analyzed populations.

Conclusions:

• Dupilumab demonstrated significant and sustained improvements in multiple lung function measures in children aged 6-11 with uncontrolled, moderate-to-severe type 2 asthma.
• The findings suggest dupilumab is an effective therapeutic option for improving lung function and potentially mitigating long-term complications associated with impaired lung growth in pediatric asthma.
• Early and sustained lung function improvements highlight the potential of dupilumab in managing pediatric asthma and its impact on lung development.